Showing results (151-160 of 542) with videos related to
Sort By:
Pageof 55
British Journal of Clinical Pharmacology|November 1, 1994
Pharmacokinetics of co-administered didanosine and stavudine in HIV-seropositive male patientsR D Seifert, M B Stewart, J J Sramek, et al.Life Sciences|January 1, 1996
Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's diseaseJ J Sramek, R Anand, T S Wardle, et al.Life Sciences|January 1, 1995
Safety and tolerability of CI-979 in patients with Alzheimer's diseaseJ J Sramek, A J Sedman, P A Reece, et al.Journal of Human Hypertension|November 1, 1995
Anti-hypertensive effects of intravenous compared with oral captoprilJ J Sramek, J J Brennan, D R Much, et al.Biological Psychiatry|April 1, 1984
Effects of chronic desipramine on plasma norepinephrine concentrations and cardiovascular parameters in elderly depressed women: a preliminary reportN R Cutler, A P Zavadil, M Linnoila, et al.Cortex; a Journal Devoted to the Study of the Nervous System and Behavior|March 1, 1984
Alterations in auditory processing of speech stimuli during aging in healthy subjectsC L Grady, A M Grimes, A Pikus, et al.Life Sciences|January 1, 1995
A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesteraseJ J Sramek, G A Block, S A Reines, et al.Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 1, 1984
Low dose bromocriptine: a study of acute effects in chronic mediated schizophrenicsN R Cutler, D V Jeste, C A Kaufmann, et al.Journal of Geriatric Psychiatry and Neurology|October 1, 1991
A new assessment tool for neuropsychopharmacologic research: the Computerized Neuropsychological Test BatteryA E Veroff, N R Cutler, J J Sramek, et al.Life Sciences|May 19, 1998
Safety and tolerability of metrifonate in patients with Alzheimer's disease: results of a maximum tolerated dose studyN R Cutler, S S Jhee, P Cyrus, et al.Pageof 55